{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T04:02:13Z","timestamp":1794024133172,"version":"4.8.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T00:00:00Z","timestamp":1694044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T00:00:00Z","timestamp":1694044800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The development of a universal influenza vaccine to elicit broad immune responses is essential in reducing disease burden and pandemic impact. In this study, the mosaic vaccine design strategy and genetic algorithms were utilized to optimize the seasonal influenza A virus (H1N1, H3N2) hemagglutinin (HA) and neuraminidase (NA) antigens, which also contain most potential T-cell epitopes. These mosaic immunogens were then expressed as virus-like particles (VLPs) using the baculovirus expression system. The immunogenicity and protection effectiveness of the mosaic VLPs were compared to the commercial quadrivalent inactivated influenza vaccine (QIV) in the mice model. Strong cross-reactive antibody responses were observed in mice following two doses of vaccination with the mosaic VLPs, with HI titers higher than 40 in 15 of 16 tested strains as opposed to limited cross HI antibody levels with QIV vaccination. After a single vaccination, mice also show a stronger level of cross-reactive antibody responses than the QIV. The QIV vaccinations only elicited NI antibodies to a small number of vaccine strains, and not even strong NI antibodies to its corresponding vaccine components. In contrast, the mosaic VLPs caused robust NI antibodies to all tested seasonal influenza virus vaccine strains. Here, we demonstrated the mosaic vaccines induce<jats:strike>s<\/jats:strike> stronger cross-reactive antibodies and robust more T-cell responses compared to the QIV. The mosaic VLPs also provided protection against challenges with ancestral influenza A viruses of both H1 and H3 subtypes. These findings indicated that the mosaic VLPs were a promising strategy for developing a broad influenza vaccine in future.<\/jats:p>","DOI":"10.1038\/s41541-023-00728-5","type":"journal-article","created":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T13:02:42Z","timestamp":1694091762000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["A mosaic influenza virus-like particles vaccine provides broad humoral and cellular immune responses against influenza A viruses"],"prefix":"10.1038","volume":"8","author":[{"given":"Xuejie","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangliang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuolin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuming","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minchao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0367-6888","authenticated-orcid":false,"given":"Huanle","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2000-7053","authenticated-orcid":false,"given":"Caijun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huacheng","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9279-0916","authenticated-orcid":false,"given":"Yuelong","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,7]]},"reference":[{"key":"728_CR1","doi-asserted-by":"publisher","first-page":"122","DOI":"10.3390\/v11020122","volume":"11","author":"ME Francis","year":"2019","unstructured":"Francis, M. E., King, M. L. & Kelvin, A. A. Back to the future for influenza preimmunity\u2014looking back at influenza virus history to infer the outcome of future infections. Viruses 11, 122 (2019).","journal-title":"Viruses"},{"key":"728_CR2","first-page":"E64","volume":"60","author":"M Martini","year":"2019","unstructured":"Martini, M., Gazzaniga, V., Bragazzi, N. L. & Barberis, I. The Spanish influenza pandemic: a lesson from history 100 years after 1918. J. Prev. Med. Hyg. 60, E64\u2013E67 (2019).","journal-title":"J. Prev. Med. Hyg."},{"key":"728_CR3","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1093\/infdis\/jiz543","volume":"221","author":"B Flannery","year":"2020","unstructured":"Flannery, B. et al. Spread of antigenically drifted influenza A(H3N2) viruses and vaccine effectiveness in the United States during the 2018\u20132019 season. J. Infect. Dis. 221, 8\u201315 (2020).","journal-title":"J. Infect. Dis."},{"key":"728_CR4","doi-asserted-by":"publisher","first-page":"101124","DOI":"10.1016\/j.arr.2020.101124","volume":"62","author":"Y Cheng","year":"2020","unstructured":"Cheng, Y. et al. Effects of influenza vaccination on the risk of cardiovascular and respiratory diseases and all-cause mortality. Ageing Res. Rev. 62, 101124 (2020).","journal-title":"Ageing Res. Rev."},{"key":"728_CR5","doi-asserted-by":"crossref","unstructured":"Lopez, C. E. & Legge, K. L. Influenza A virus vaccination: immunity, protection, and recent advances toward a universal vaccine. Vaccines 8, 434 (2020).","DOI":"10.3390\/vaccines8030434"},{"key":"728_CR6","doi-asserted-by":"publisher","first-page":"e0223784","DOI":"10.1371\/journal.pone.0223784","volume":"14","author":"CB Stauft","year":"2019","unstructured":"Stauft, C. B. et al. Live-attenuated H1N1 influenza vaccine candidate displays potent efficacy in mice and ferrets. PLoS ONE 14, e0223784 (2019).","journal-title":"PLoS ONE"},{"key":"728_CR7","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/S0140-6736(20)32014-6","volume":"396","author":"BJ Ward","year":"2020","unstructured":"Ward, B. J. et al. Efficacy, immunogenicity, and safety of a plant-derived, quadrivalent, virus-like particle influenza vaccine in adults (18\u201364 years) and older adults (\u226565 years): two multicentre, randomised phase 3 trials. Lancet 396, 1491\u20131503 (2020).","journal-title":"Lancet"},{"key":"728_CR8","first-page":"1784","volume":"326","author":"J Abbasi","year":"2021","unstructured":"Abbasi, J. Flu vaccine candidate elicits enhanced immune response. J. Am. Med. Assoc. 326, 1784 (2021).","journal-title":"J. Am. Med. Assoc."},{"key":"728_CR9","doi-asserted-by":"publisher","first-page":"2874","DOI":"10.1016\/j.ymthe.2022.07.013","volume":"30","author":"K Bahl","year":"2022","unstructured":"Bahl, K. et al. Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses. Mol. Ther. 30, 2874 (2022).","journal-title":"Mol. Ther."},{"key":"728_CR10","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/371037a0","volume":"371","author":"PA Bullough","year":"1994","unstructured":"Bullough, P. A., Hughson, F. M., Skehel, J. J. & Wiley, D. C. Structure of influenza haemagglutinin at the pH of membrane fusion. Nature 371, 37\u201343 (1994).","journal-title":"Nature"},{"key":"728_CR11","first-page":"285","volume":"5","author":"S Qui\u00f1ones-Parra","year":"2014","unstructured":"Qui\u00f1ones-Parra, S., Loh, L., Brown, L. E., Kedzierska, K. & Valkenburg, S. A. Universal immunity to influenza must outwit immune evasion. Front. Microbiol. 5, 285 (2014).","journal-title":"Front. Microbiol."},{"key":"728_CR12","doi-asserted-by":"crossref","unstructured":"Biswas, M., Yamazaki, T., Chiba, J. & Akashi-Takamura, S. Broadly neutralizing antibodies for influenza: passive immunotherapy and intranasal vaccination. Vaccines 8, 424 (2020).","DOI":"10.3390\/vaccines8030424"},{"key":"728_CR13","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/s41586-021-03365-x","volume":"592","author":"S Boyoglu-Barnum","year":"2021","unstructured":"Boyoglu-Barnum, S. et al. Quadrivalent influenza nanoparticle vaccines induce broad protection. Nature 592, 623\u2013628 (2021).","journal-title":"Nature"},{"key":"728_CR14","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1126\/science.aay0678","volume":"366","author":"D Stadlbauer","year":"2019","unstructured":"Stadlbauer, D. et al. Broadly protective human antibodies that target the active site of influenza virus neuraminidase. Science 366, 499\u2013504 (2019).","journal-title":"Science"},{"key":"728_CR15","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/nm1461","volume":"13","author":"W Fischer","year":"2007","unstructured":"Fischer, W. et al. Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat. Med. 13, 100\u2013106 (2007).","journal-title":"Nat. Med."},{"key":"728_CR16","doi-asserted-by":"publisher","first-page":"13300","DOI":"10.1128\/JVI.01532-14","volume":"88","author":"A Kamlangdee","year":"2014","unstructured":"Kamlangdee, A., Kingstad-Bakke, B., Anderson, T. K., Goldberg, T. L. & Osorio, J. E. Broad protection against avian influenza virus by using a modified vaccinia Ankara virus expressing a mosaic hemagglutinin gene. J. Virol. 88, 13300\u201313309 (2014).","journal-title":"J. Virol."},{"key":"728_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21508-6","volume":"12","author":"BL Bullard","year":"2021","unstructured":"Bullard, B. L. et al. Epigraph hemagglutinin vaccine induces broad cross-reactive immunity against swine H3 influenza virus. Nat. Commun. 12, 1203 (2021).","journal-title":"Nat. Commun."},{"key":"728_CR18","doi-asserted-by":"publisher","first-page":"1014122","DOI":"10.3389\/fmicb.2022.1014122","volume":"13","author":"X Liu","year":"2022","unstructured":"Liu, X. et al. Strategies targeting hemagglutinin cocktail as a potential universal influenza vaccine. Front. Microbiol. 13, 1014122 (2022).","journal-title":"Front. Microbiol."},{"key":"728_CR19","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1053\/j.ajkd.2022.01.425","volume":"80","author":"HJ Manley","year":"2022","unstructured":"Manley, H. J. et al. Seroresponse to inactivated and recombinant influenza vaccines among maintenance hemodialysis patients. Am. J. Kidney Dis. 80, 309\u2013318 (2022).","journal-title":"Am. J. Kidney Dis."},{"key":"728_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-022-00492-y","volume":"7","author":"BL Bullard","year":"2022","unstructured":"Bullard, B. L. et al. An epitope-optimized human H3N2 influenza vaccine induces broadly protective immunity in mice and ferrets. NPJ Vaccines 7, 65 (2022).","journal-title":"NPJ Vaccines"},{"key":"728_CR21","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1097\/INF.0b013e3182367662","volume":"30","author":"S Black","year":"2011","unstructured":"Black, S. et al. Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children. Pediatr. Infect. Dis. J. 30, 1081\u20131085 (2011).","journal-title":"Pediatr. Infect. Dis. J."},{"key":"728_CR22","doi-asserted-by":"publisher","first-page":"ofv067","DOI":"10.1093\/ofid\/ofv067","volume":"2","author":"A Benoit","year":"2015","unstructured":"Benoit, A. et al. Hemagglutination inhibition antibody titers as a correlate of protection against seasonal A\/H3N2 influenza disease. Open Forum Infect. Dis. 2, ofv067 (2015).","journal-title":"Open Forum Infect. Dis."},{"key":"728_CR23","doi-asserted-by":"publisher","first-page":"135","DOI":"10.15585\/mmwr.mm6806a2","volume":"68","author":"JD Doyle","year":"2019","unstructured":"Doyle, J. D. et al. Interim estimates of 2018-19 seasonal influenza vaccine effectiveness\u2014United States, February 2019. MMWR Morb. Mortal. Wkly. Rep. 68, 135\u2013139 (2019).","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"728_CR24","doi-asserted-by":"publisher","first-page":"177","DOI":"10.15585\/mmwr.mm6907a1","volume":"69","author":"FS Dawood","year":"2020","unstructured":"Dawood, F. S. et al. Interim estimates of 2019-20 seasonal influenza vaccine effectiveness\u2014United States, February 2020. MMWR Morb. Mortal. Wkly. Rep. 69, 177\u2013182 (2020).","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"728_CR25","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1080\/21645515.2018.1482172","volume":"14","author":"H Lee","year":"2018","unstructured":"Lee, H., Shim, E. H. & You, S. Immunodominance hierarchy of influenza subtype-specific neutralizing antibody response as a hurdle to effectiveness of polyvalent vaccine. Hum. Vaccin. Immunother. 14, 2537\u20132539 (2018).","journal-title":"Hum. Vaccin. Immunother."},{"key":"728_CR26","doi-asserted-by":"publisher","first-page":"132155","DOI":"10.1172\/jci.insight.132155","volume":"5","author":"RB Abreu","year":"2020","unstructured":"Abreu, R. B., Kirchenbaum, G. A., Clutter, E. F., Sautto, G. A. & Ross, T. M. Preexisting subtype immunodominance shapes memory B cell recall response to influenza vaccination. JCI Insight 5, 132155 (2020).","journal-title":"JCI Insight"},{"key":"728_CR27","doi-asserted-by":"publisher","first-page":"e0131531","DOI":"10.1371\/journal.pone.0131531","volume":"10","author":"CP Verschoor","year":"2015","unstructured":"Verschoor, C. P. et al. Microneutralization assay titres correlate with protection against seasonal influenza H1N1 and H3N2 in children. PLoS ONE 10, e0131531 (2015).","journal-title":"PLoS ONE"},{"key":"728_CR28","doi-asserted-by":"publisher","first-page":"e00417","DOI":"10.1128\/mBio.00417-16","volume":"7","author":"MJ Memoli","year":"2016","unstructured":"Memoli, M. J. et al. Evaluation of antihemagglutinin and antineuraminidase antibodies as correlates of protection in an influenza A\/H1N1 virus healthy human challenge model. mBio 7, e00417\u201300416 (2016).","journal-title":"mBio"},{"key":"728_CR29","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1093\/infdis\/jiv195","volume":"212","author":"AS Monto","year":"2015","unstructured":"Monto, A. S. et al. Antibody to influenza virus neuraminidase: an independent correlate of protection. J. Infect. Dis. 212, 1191\u20131199 (2015).","journal-title":"J. Infect. Dis."},{"key":"728_CR30","doi-asserted-by":"publisher","first-page":"729914","DOI":"10.3389\/fmicb.2021.729914","volume":"12","author":"X Deng","year":"2021","unstructured":"Deng, X. et al. Tetrameric neuraminidase of influenza A virus is required to induce protective antibody responses in mice. Front. Microbiol. 12, 729914 (2021).","journal-title":"Front. Microbiol."},{"key":"728_CR31","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3389\/fmicb.2020.00135","volume":"11","author":"OA Vogel","year":"2020","unstructured":"Vogel, O. A. & Manicassamy, B. Broadly protective strategies against influenza viruses: universal vaccines and therapeutics. Front. Microbiol. 11, 135 (2020).","journal-title":"Front. Microbiol."},{"key":"728_CR32","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.virol.2019.07.008","volume":"535","author":"K-H Kim","year":"2019","unstructured":"Kim, K.-H. et al. Neuraminidase expressing virus-like particle vaccine provides effective cross protection against influenza virus. Virology 535, 179\u2013188 (2019).","journal-title":"Virology"},{"key":"728_CR33","doi-asserted-by":"publisher","first-page":"6869","DOI":"10.1073\/pnas.84.19.6869","volume":"84","author":"BE Johansson","year":"1987","unstructured":"Johansson, B. E., Moran, T. M. & Kilbourne, E. D. Antigen-presenting B cells and helper T cells cooperatively mediate intravirionic antigenic competition between influenza A virus surface glycoproteins. Proc. Natl. Acad. Sci. USA 84, 6869\u20136873 (1987).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"728_CR34","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.virol.2012.06.003","volume":"432","author":"JD Easterbrook","year":"2012","unstructured":"Easterbrook, J. D. et al. Protection against a lethal H5N1 influenza challenge by intranasal immunization with virus-like particles containing 2009 pandemic H1N1 neuraminidase in mice. Virology 432, 39\u201344 (2012).","journal-title":"Virology"},{"key":"728_CR35","doi-asserted-by":"publisher","first-page":"e02556","DOI":"10.1128\/mBio.02556-14","volume":"6","author":"TJ Wohlbold","year":"2015","unstructured":"Wohlbold, T. J. et al. Vaccination with adjuvanted recombinant neuraminidase induces broad heterologous, but not heterosubtypic, cross-protection against influenza virus infection in mice. mBio 6, e02556 (2015).","journal-title":"mBio"},{"key":"728_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/srep45043","volume":"7","author":"T Sakai","year":"2017","unstructured":"Sakai, T., Nishimura, S. I., Naito, T. & Saito, M. Influenza A virus hemagglutinin and neuraminidase act as novel motile machinery. Sci. Rep. 7, 45043 (2017).","journal-title":"Sci. Rep."},{"key":"728_CR37","doi-asserted-by":"crossref","unstructured":"Chiu, C., Ellebedy, A. H., Wrammert, J. & Ahmed, R. B Cell Responses to Influenza Infection and Vaccination. in Influenza Pathogenesis and Control \u2014Volume II (eds Oldstone, M. B. A. & Compans, R. W.) 381\u2013398 (Springer International Publishing, 2015).","DOI":"10.1007\/82_2014_425"},{"key":"728_CR38","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.3389\/fimmu.2019.01400","volume":"10","author":"M Auladell","year":"2019","unstructured":"Auladell, M. et al. Recalling the future: immunological memory toward unpredictable influenza viruses. Front. Immunol. 10, 1400 (2019).","journal-title":"Front. Immunol."},{"key":"728_CR39","doi-asserted-by":"publisher","first-page":"E33","DOI":"10.3390\/vaccines4040033","volume":"4","author":"J Spitaels","year":"2016","unstructured":"Spitaels, J., Roose, K. & Saelens, X. Influenza and memory T cells: how to awake the force. Vaccines 4, E33 (2016).","journal-title":"Vaccines"},{"key":"728_CR40","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.jcv.2019.08.009","volume":"119","author":"JM Jansen","year":"2019","unstructured":"Jansen, J. M., Gerlach, T., Elbahesh, H., Rimmelzwaan, G. F. & Saletti, G. Influenza virus-specific CD4+ and CD8+ T cell-mediated immunity induced by infection and vaccination. J. Clin. Virol. 119, 44\u201352 (2019).","journal-title":"J. Clin. Virol."},{"key":"728_CR41","first-page":"399","volume":"386","author":"KD Zens","year":"2015","unstructured":"Zens, K. D. & Farber, D. L. Memory CD4 T cells in influenza. Curr. Top. Microbiol. Immunol. 386, 399\u2013421 (2015).","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"728_CR42","doi-asserted-by":"publisher","first-page":"6363","DOI":"10.1016\/j.vaccine.2009.01.016","volume":"27","author":"GF Rimmelzwaan","year":"2009","unstructured":"Rimmelzwaan, G. F., Kreijtz, J. H. C. M., Bodewes, R., Fouchier, R. A. M. & Osterhaus, A. D. M. E. Influenza virus CTL epitopes, remarkably conserved and remarkably variable. Vaccine 27, 6363\u20136365 (2009).","journal-title":"Vaccine"},{"key":"728_CR43","doi-asserted-by":"publisher","first-page":"374","DOI":"10.4161\/bioe.23573","volume":"4","author":"DE Cargnelutti","year":"2013","unstructured":"Cargnelutti, D. E., S\u00e1nchez, M. V., Mattion, N. M. & Scodeller, E. A. Development of a universal CTL-based vaccine for influenza. Bioengineered 4, 374\u2013378 (2013).","journal-title":"Bioengineered"},{"key":"728_CR44","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1172\/JCI63689","volume":"122","author":"KK McKinstry","year":"2012","unstructured":"McKinstry, K. K. et al. Memory CD4+ T cells protect against influenza through multiple synergizing mechanisms. J. Clin. Investig. 122, 2847\u20132856 (2012).","journal-title":"J. Clin. Investig."},{"key":"728_CR45","doi-asserted-by":"publisher","first-page":"e1003207","DOI":"10.1371\/journal.ppat.1003207","volume":"9","author":"BJ Laidlaw","year":"2013","unstructured":"Laidlaw, B. J. et al. Cooperativity between CD8+ T cells, non-neutralizing antibodies, and alveolar macrophages is important for heterosubtypic influenza virus immunity. PLoS Pathog. 9, e1003207 (2013).","journal-title":"PLoS Pathog."},{"key":"728_CR46","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1093\/infdis\/jiu654","volume":"211","author":"KG-I Mohn","year":"2015","unstructured":"Mohn, K. G.-I. et al. Longevity of B-cell and T-cell responses after live attenuated influenza vaccination in children. J. Infect. Dis. 211, 1541\u20131549 (2015).","journal-title":"J. Infect. Dis."},{"key":"728_CR47","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1128\/CVI.00156-06","volume":"13","author":"VC Huber","year":"2006","unstructured":"Huber, V. C. et al. Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenza. Clin. Vaccin. Immunol. 13, 981\u2013990 (2006).","journal-title":"Clin. Vaccin. Immunol."},{"key":"728_CR48","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/j.1600-065X.1997.tb01009.x","volume":"159","author":"W Gerhard","year":"1997","unstructured":"Gerhard, W., Mozdzanowska, K., Furchner, M., Washko, G. & Maiese, K. Role of the B-cell response in recovery of mice from primary influenza virus infection. Immunol. Rev. 159, 95\u2013103 (1997).","journal-title":"Immunol. Rev."},{"key":"728_CR49","doi-asserted-by":"publisher","first-page":"4347","DOI":"10.1128\/jvi.71.6.4347-4355.1997","volume":"71","author":"K Mozdzanowska","year":"1997","unstructured":"Mozdzanowska, K., Furchner, M., Washko, G., Mozdzanowski, J. & Gerhard, W. A pulmonary influenza virus infection in SCID mice can be cured by treatment with hemagglutinin-specific antibodies that display very low virus-neutralizing activity in vitro. J. Virol. 71, 4347\u20134355 (1997).","journal-title":"J. Virol."},{"key":"728_CR50","doi-asserted-by":"publisher","first-page":"5885","DOI":"10.1016\/j.vaccine.2020.07.008","volume":"38","author":"N Kavian","year":"2020","unstructured":"Kavian, N., Hachim, A., Poon, L. L. M. & Valkenburg, S. A. Vaccination with ADCC activating HA peptide epitopes provides partial protection from influenza infection. Vaccine 38, 5885\u20135890 (2020).","journal-title":"Vaccine"},{"key":"728_CR51","doi-asserted-by":"publisher","first-page":"e03617","DOI":"10.1128\/mBio.03617-20","volume":"12","author":"EK Roubidoux","year":"2021","unstructured":"Roubidoux, E. K. et al. Mutations in the hemagglutinin stalk domain do not permit escape from a protective, stalk-based vaccine-induced immune response in the mouse model. mBio 12, e03617\u2013e03620 (2021).","journal-title":"mBio"},{"key":"728_CR52","doi-asserted-by":"publisher","unstructured":"Gao, J., Couzens, L. & Eichelberger, M. C. Measuring influenza neuraminidase inhibition antibody titers by enzyme-linked lectin assay. J. Vis. Exp. 54573. https:\/\/doi.org\/10.3791\/54573 (2016).","DOI":"10.3791\/54573"}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-023-00728-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-023-00728-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-023-00728-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T05:02:31Z","timestamp":1700456551000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-023-00728-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,7]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["728"],"URL":"https:\/\/doi.org\/10.1038\/s41541-023-00728-5","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,7]]},"assertion":[{"value":"13 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"132"}}